A single-item indicator of disease activity over an extended period of time, the Manitoba Infl ammatory Bowel Disease Index (MIBDI), is introduced and compared against several standard measures for assessing activity in patients with Crohn ' s disease (CD) and ulcerative colitis (UC).
INTRODUCTION
Assessing disease activity in in ammatory bowel disease (IBD) is an important aspect of clinical trials. It would seem to be a straightforward task to determine whether individuals with IBD have active disease and disease activity changes over time. However, there is no single indicator of disease activity that is widely adopted as the gold standard. One popular clinical index is the Crohn ' s Disease Activity Index (CDAI) (1) , which identies symptoms and is enhanced by a single objective measure of hematocrit. Other indexes, such as the Harvey -Bradshaw Index (HB) (2) for Crohn ' s disease (CD) and the Powell -Tuck Index (PT) (3) for ulcerative colitis (UC), are based on selfreports of active disease symptoms at the time of assessment with cursory clinical examination. When used in clinical trials they are re-administered at regular intervals to assess changes in disease activity over time. e importance of including a self-assessment of the patient ' s health has been shown by Drossman et al. (4) . ey found that 10 .1038/ajg. 2009.197 The Manitoba IBD Index: Evidence for a New and Simple Indicator of IBD Activity
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The Manitoba IBD Index self-assessment scales for IBD correlated well with physician ratings of disease activity, and accounted for a high percentage of the variation in overall health status. Similarly, Higgins et al. (5) showed the value of patient de nition of clinically meaningful improvement and remission status in IBD.
Serological measures, such as the C-reactive protein (CRP) or serum hemoglobin and albumin, are also used as markers of disease activity. Although an elevated CRP re ects current active in ammation, low serum hemoglobin or albumin may re ect IBD activity over time or other health problems. Imaging modalities have also been used to assess disease activity. is approach avoids the subjective element of symptom inquiry, but it correlates poorly with active symptoms, and it is problematic to repeat imaging, endoscopic, or radiological methods for sequential assessment of activity (6, 7) .
Although assessing disease activity in clinical trials is imperfect, there is yet another layer of complexity to assessing activity in natural history or cohort studies. Individuals followed prospectively and at regular intervals have provided key outcome data from regions as disparate as Manitoba, Canada (8) , Olmsted County in the United States (9) , Norway (10) , and multiple European centers (11) . However, cohort research typically studies participants over longer intervals (for example, 6, 12, or 24 months) to understand the natural history and ' real-life ' experiences with the disease. Prospective studies would be enhanced by having an index that could better characterize disease activity over these longer time periods. As the current clinical indexes in use have very short time frames (usually 1 day to a few weeks) and there is no available measure of extended disease activity, we endeavored to develop a brief, informative activity index, using patient assessment of disease activity, to address this need. e purpose of this study is to propose a new self-report measure of disease activity and compare it with the existing measures, both cross-sectionally and over time. e index was assessed in relation to a variety of other measures that relate to disease activity either directly or indirectly, including physical symptoms, biological markers, IBD medication use, and daily productivity loss.
METHODS

Cohort participants
e Manitoba IBD Cohort Study was initiated in 2002, drawing on participants from the University of Manitoba IBD Research Registry. Most participants were at least 18 years old (with a small number nearing their 18th birthday at the time of entry into the study), and diagnosed within the previous 7 years, the latter to capture relatively recent onset. e population-based Registry was established in 1995. Residents of the province of Manitoba, Canada (population approximately 1,150,000) identi ed as having IBD through the administrative health database of Manitoba Health (the government agency that provides comprehensive health coverage to all residents) were eligible for inclusion in the Registry. Of those eligible, that is, all those with IBD in the province, just over half participated in the Registry (12) .
e Manitoba IBD Cohort Study was approved by the University of Manitoba Health Research Ethics Board and participants provided written informed consent for their involvement in the research. At the time of study recruitment, there were 3,192 participants in the Research Registry, of which 606 were eligible for this study, given the age and recent onset criteria. Of those, 418 could be contacted and enrolled over an 18-month period.
Complete data were obtained in the rst contact of the longitudinal Manitoba IBD Cohort from 388 of those enrolled, and they have subsequently served as the Cohort. More details on the creation of this sample are provided in an earlier report by our group (13) . Participants were similar in age and sex distribution to those with parallel duration of disease in the University of Manitoba IBD Epidemiology Database, an administrative data set that includes all those in the province with IBD, suggesting excellent representativeness of the cohort. e data for this study were obtained from 353 participants who provided information at three measurement occasions: 0-month (baseline), 12-month, and 24-month assessments.
Disease activity measures
e Manitoba IBD Index (MIBDI) was designed to assess disease activity based on patient report of symptom persistence for the previous 6 months, using a 6-level response format. It used frequency anchors to provide more consistent reporting. Participants were asked to respond to the following: " In the past 6 months my disease has been (a) constantly active, giving me symptoms every day; (b) o en active, giving me symptoms most days; (c) sometimes active, giving me symptoms on some days (for instance 1 -2 days / week); (d) occasionally active, giving me symptoms 1 -2 days / month; (e) rarely active, giving me symptoms on a few days in the past 6 months; and (f) I was well in the past 6 months, what I consider a remission or absence of symptoms. " A dichotomous disease activity measure was de ned as follows: active disease included experiencing symptoms constantly to occasionally (responses a to d), and inactive disease as experiencing infrequent symptoms or feeling well (responses e or f).
Clinical indexes
e HB and PT multi-item measures were administered during each of the annual clinical interviews; each measure describes symptom levels at the time of assessment. e measures are 6 and 8 items in length, respectively, and the items are summed to provide a summary index score. Scores greater than or equal to four on either scale are indicative of active disease (5, 14) .
Another measure of disease activity that was compared with the MIBDI was the 32-item In ammatory Bowel Disease Questionnaire (IBDQ) (15) , which summarizes physical, social, and emotional health in the preceding 2 weeks as reported from the patient ' s perspective (16) . e IBDQ yields a total score, as well as scores for four subdomains: Bowel Symptoms,
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Systemic Symptoms, Emotional Function, and Social Function. Responses are made on a 7-point Likert scale (0 = " All of the time, " 7 = " None of the time " ). Higher total IBDQ scores (over and including 170) are associated with remission, and lower scores ( < 170) are associated with moderate-to-severe IBD symptoms (17) .
IBD symptom severity
e severity of nine common IBD symptoms over the previous 6 months were rated using a ve-point scale ranging from " Not at all " to " Extremely. " ey included the following: abdominal pain, diarrhea, problems sleeping, tiredness, joint pain, urgency to have bowel movements, loss of appetite, weight loss, and the presence of blood in stool. Participants were also asked about the average number of bowel movements per day they had in the past month. A single item from the McGill Pain Questionnaire (18) was also used, asking participants if they had any persistent pain (answered as yes / no) related to IBD over the past 2 weeks.
Biological markers and medication use
e CRP level is o en used in chronic in ammatory diseases as a marker of active in ammation; it is typically understood to be an acute phase reactant (19) . As anemia can be secondary to a number of factors in IBD, its presence can certainly be a marker of ongoing active disease. Furthermore, those with normal serum hemoglobin are less likely to have severely active disease. CRP and hemoglobin were obtained through a blood draw at the time of the clinical interview. For CRP, a " normal " level was de ned as a value from 0 to 7 mg / l, with CRP values higher than 7 mg / l being classi ed as " high CRP. " For the serum hemoglobin readings, values higher than or equal to 120 g / l were classi ed as " normal, " and values lower than 120 g / l were classi ed as " low serum hemoglobin. " e use of prednisone and in iximab can also serve as markers of active disease. Because of their side e ect pro les, they would only be initiated for treatment if a patient was truly symptomatic with active disease. Prednisone has not typically been useful to maintain disease remission and hence is used primarily to settle active disease, with the exception of a small subset who are prednisone-dependent (i.e., can only sustain inactive disease if prednisone is maintained). In iximab has been proven to have utility to maintain remission (20) but its persistent use implies that the patient at one time had sufciently active disease to warrant prescription. Hence, recent initiation of in iximab can identify recently active disease even though long-term usage does not (20) . Participants were asked whether they had used any of these medications in the previous 6 months, including number of weeks of use and maximum daily dosage.
Reduction in activity / disability
Recent illness-related disability was assessed based on three questions drawn from a National Health Survey: (21) " In the last 14 days (a) did you stay in bed for all or most of the day due to illness or injury; (b) were there any days that you cut down on things you normally do because of illness or injury; (c) were there any days when it took extra e ort to perform up to your usual level at work or at your other daily activities. "
Clinical sample
To further assess the validity of the MIBDI, a secondary investigation was undertaken for an independent sample of 80 consecutive IBD patients attending an outpatient hospital clinic.
ese patients completed the MIBDI in addition to routine clinical measures, including either the HB or PT, depending on their diagnosis. Retrospective chart reviews were done (by CNB) to determine patient patterns of disease over the previous 6 months. Patient disease was categorized as active or inactive during that period, based on indications of disease are including symptom reporting, change in medication, histology, or interventions required. e reviewer was blind to the MIBDI score.
Statistical methods
Summary statistics, including means, standard deviations, Spearman correlations, and the percentage of individuals classi ed as active and inactive, were computed for all of the disease activity measures included in the study. Sensitivity and speci city (22) were estimated for the MIBDI. Speci cally, the proportion of respondents with active and inactive disease as classi ed by the MIBDI was compared with the proportion of respondents with active and inactive disease as classi ed by the IBDQ total score (IBDQ < 170 = active (23) ) and to the proportion determined to be active based on the HB or the PT (HB or PT ≥ 4 = active (24) ). Sensitivity is de ned as the likelihood the MIBDI positively identi ed individuals with active disease when disease status was identi ed as active by one of the other measures, with values closer to 1.0 indicating excellent identi cation of active disease. Speci city is de ned as the likelihood the MIBDI identi ed individuals with inactive disease when the other measures identi ed inactive disease, with values closer to 1.0 indicating excellent identi cation of inactive disease. Test-retest reliability was assessed using both the Spearman ' s correlation and the -statistic.
Discriminant function analyses were conducted to assess validity. Analyses were carried out for each measurement occasion (0, 12, and 24 months) and each subtype of IBD (CD, UC). A discriminant function analysis is used to predict the probability of group membership from a set of predictors (25) . In this study, individuals were classi ed into active or inactive disease groups using responses from the MIBDI. e predictors were as follows: clinical indexes of current disease activity, past 6-month severity ratings of common IBD-related symptoms, average daily bowel movements over the previous month, persistent pain intensity related to IBD in the past 2 weeks, recent restriction of activities due to illness, high current CRP, low current hemoglobin levels, and reported use of in iximab or prednisone in the past 6 months. A predictor was considered to be a good discriminatory variable of active
INFLAMMATORY BOWEL DISEASE
The Manitoba IBD Index and inactive disease as per the MIBDI if it showed a discriminant function coe cient of at least 0.35 in absolute value (26) ; it was considered to be a consistent discriminatory variable if the coe cient was 0.35 or higher for at least two of the three assessment points. ese coe cients re ect correlations between the proposed predictor variables and the discriminant function (the linear combination of predictor variables that classi es cases, in this instance inactive vs. active disease status according to the MIBDI) (26) .
RESULTS
At study entry (baseline), the mean age of participants was 41 years (s.d. = 14.53, range 17 -79 years), and 59 % were female.
e sample was 95 % Caucasian, with few having self-described backgrounds as East Indian, Hispanic, or Metis (mixed aboriginal and European background). Two-thirds of participants were married (67.5 % ), 53.6 % were employed full time, and 27.5 % had a university degree. Chart review con rmed that 184 had CD, and 169 had UC; 18 with indeterminate colitis were not included in this analysis. e average duration of disease was 4.3 years (s.d. = 2.1). Forty-eight percent were taking 5-ASA, 21 % were taking immunosuppresants, and 5 % were taking prednisone at study entry. Table 1 presents the proportion of respondents reporting each of the six levels of symptom activity on the MIBDI at each of the 0-, 12-, and 24-month assessment periods. e reporting pattern of disease activity from constantly active disease to remission during the past 6 months clearly shows a normal distribution, which is not surprising for this population-based cohort. e distribution was consistent across the three assessment periods. Furthermore, there was stability across time regarding the proportion of individuals who were relatively well (i.e., 16 -21 % no symptoms; 13 -20 % rare symptoms), had daily symptoms (i.e., 10 % ), or who had symptoms occasionally to o en (50 -55 % ). Table 2 reports summary statistics (i.e., means and s.d.) for the four disease activity measures (the MIBDI, HB, PT, and IBDQ total score) for each of the three assessment periods (0-month, 12-month, and 24-month), as well as their intercorrelations and the percentage of individuals classi ed as " inactive " or " active " for each measure. e correlation between the MIBDI and the other disease activity measures is in the medium range (27) . Each of the four measures showed a consistent proportion of individuals who were classi ed as active over time. e MIBDI showed similar rates of classi cation compared with the HB and PT classi cations, but identi ed a higher proportion of individuals as having active disease compared with the other disease activity measures. is seems reasonable given the considerably longer time period encompassed by the MIBDI. e sensitivity and speci city results, shown in Table 3 , suggested good sensitivity and modest speci city for the Manitoba IBD Index.
e MIBDI had good sensitivity in describing active vs. inactive disease when compared with the HB, PT, and IBDQ indexes, with the majority of values ranging from 0.84 to 0.90 across the 0-, 12-, and 24-month assessment periods. Speci city ranged from 0.51 to 0.68 when compared with the HB, PT, and IBDQ indexes. is lower speci city was not unexpected as the MIBDI was assessing activity over 6 months, whereas the HB and PT indexes were assessing activity at a single time point. Respondents could be identi ed by the MIBDI as having active disease over the last 6 months even if the disease was not active in the most recent few days to few weeks.
ere was strong test-retest reliability of the MIBDI in the 1-week retest subsample. e Spearman ' s correlation between the MIBDI scores at the two measurement occasions was high ( r = 0.81, 95 % con dence interval: 0.76 -0.86), and the -value for active vs. inactive categorization at these two measurement points was also good (0.76; 95 % con dence interval: 0.67 -0.85).
On the basis of independent sample of 80 clinic patients, 67.50 % ( n = 54) had a positive concordance between their MIBDI and HB or PT disease activity categorization, 26.25 % ( n = 21) had a discordant relationship between these two disease activity measures, and 6.25 % ( n = 5) could not be assessed on the HB or PT due to the presence of stomas. Chart review data were consistent with the disease activity categorization of disease activity. Overall, the MIBDI was able to provide accurate disease activity classi cation for the previous 6-month period for 96 % of this clinic sample, relative to chart information. e sensitivity of the MIBDI in this clinical sample was 0.85 (95 % con dence interval: 0.70, 0.94), and the speci city was 0.58 (0.41, 0.73). e sensitivity of the MIBDI compared with the chart review in this indexes for 100 % of the 54 patients with concordant HB / PT and MIBDI ratings. Of those with discordant ratings, chart review data from 86 % of these patients was consistent with the MIBDI categorization of disease activity over the HB or PT. Furthermore, the remaining ve patients with stomas also had concordance between the chart indications of active (or inactive) disease in the previous 6 months and MIBDI 
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The Manitoba IBD Index clinical sample was 0.92 (0.81, 0.98) and the speci city was 0.79 (0.59, 0.91). e results of the discriminant function analyses are presented in Tables 4 and 5 for those with CD and UC, respectively. For both groups of patients, common discriminating variables that categorized respondents as active or inactive as per the MIBDI consistently across time included clinical indexes (HB and PT), all four of the IBDQ subscales (bowel, systemic symptoms, social functioning, emotional health), several of the IBD symptom severity ratings (abdominal pain, tiredness, diarrhea, urgency of bowel movements), and recent pain intensity.
For CD, unique discriminators were loss of appetite and weight problems. For UC patients, the presence of blood in stool during the past 6 months emerged as a unique disease activity discriminator. Several other variables showed moderate discriminatory power (e.g., days requiring extra effort), but only showed high discriminative ability for a single assessment point, and so were not considered to be consistent discriminatory variables. Medication use and blood markers were not discriminatory for extended disease activity.
DISCUSSION
Disease activity in IBD, and in particular over an extended period of time, is challenging to assess. A proposed singleitem patient-de ned disease activity measure, the MIBDI, was compared with the existing disease activity measures (i.e., HB, PT, IBDQ) with respect to sensitivity and convergent validity. e MIBDI showed a high degree of sensitivity for classifying individuals with regard to their disease activity over time compared with these existing disease activity measures, and showed excellent test-retest reliability. e correlations between the MIBDI and the HB, PT, and IBDQ indexes were, in fact, similar to those reported by Irvine et al. (23) for the IBDQ. Strong convergent validity with expected proxy measures of disease activity was found, and these relationships were consistent across a period of 2 years. Discriminant function analyses supported the MIBDI de nition of disease activity in relation to active symptoms. Additional evidence of validity for the MIBDI was established in a clinical setting, where the patient ' s report on disease in the previous 6 months using the MIBDI was highly consistent with evidence of disease status based on retrospective review of the clinical record.
There is commonly a distinction between disease activity, often reported by the patient, and disease severity, often assessed by imaging, histological assessment and the presence of certain disease characteristics (e.g., fistulas). It has been suggested that the disease activity reflected the symptomatic status of the patient, in other words their direct experience of the disease, while severity was reflected by the degree and extent of architectural changes (28) . Some patients may have active disease with little abnormality found on imaging studies, whereas others may have clear Note: values in bold text represent variables that are strong (i.e., greater than 0.35 in absolute value) discriminating variables between inactive and active disease status.
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inflammation as established by endoscopy or histology, but experience minimal symptoms. The GETAID group has repeatedly shown that endoscopic activity of CD correlates either poorly or not at all with a clinical disease activity index (6, 7, 29) . Similarly in UC, macroscopic changes at colonoscopy have correlated poorly with the PT clinical index, so an objective measure of inflammation is not necessarily reflective of a patient ' s symptoms (30) . Although some may question the validity of equating symptoms with ' true ' disease activity, this latter study shows that using an objective measure, such as macroscopic mucosal, appearance does not correlate with how the patient is feeling. Other objective measures associated with disease activity for IBD, such as fecal calprotectin (31) , gut permeability (32), or gut lavage fluid protein, have high sensitivity for the presence or absence of active disease (33) . One critique of using patient symptom report to identify their disease activity status is the notion that some symptoms may not be generated by active in ammation, but rather by functional complaints. One example is the overlap of irritable bowel syndrome (a very common condition in the community) in patients with IBD (34) . However, it has previously been shown that in general, patients with IBD are not any more likely to have IBS than the general population (8) . Preliminary research has also suggested that assumed functional complaints in IBD may in fact re ect subthreshold IBD in ammatory activity or be the result of IBD complications, such as brous strictures (35) , which further supports the value of patient report regarding their disease activity.
Certainly, patient report of problematic symptoms should and usually does encourage physicians to treat an IBD patient ' s gastrointestinal symptoms, as if they are arising from active IBD. at is, in clinical practice, most physicians tailor therapy to the symptoms described by the patient, particularly, when there are regular visits for ongoing consultation or treatment. It is symptoms that motivate patients to seek health services and to use medications to improve productivity and quality of life. People do not miss work because of macroscopic colonic disease, but do miss work because of active symptoms. Hence, the use of symptom inquiry is an important way to directly assess a patient ' s health status.
Currently available disease activity measures are in the form of patient self-report (e.g., IBDQ), clinician-administered symptom report (e.g., HB and PT), and combinations of selfreport plus objective data, such as hematocrit measurements (e.g., CDAI), endoscopic scores, or serological markers of active in ammation (36) . One of the most widely used combination measures, the CDAI, has been criticized for its lack of standardization in administration and scoring. Recommendations for change have included simplifying it to include just patient report (37) .
Self-report measures have the advantage of being quick and easy to administer, low in cost, nonintrusive, reasonably consistent over time, and relate strongly to important clinical outcomes (13) .
ese measures di er in the time 
The Manitoba IBD Index period assessed, with most IBD self-report measures considering very recent periods, ranging from the same-day assessment to the previous 2 weeks (for the IBDQ). However, there has been no evaluation of the correspondence between these same-day or recent few-week current disease activity measurements and longer-term existence of problematic symptoms and disease activity (i.e., over several months). Although the brief time frame can be useful for some purposes, the experience of persistent active disease may well have a di erent impact on the individual than a quickly resolved episode, but the brief disease activity measures do not allow di erentiation. e MIBDI captures the longer-term experience of the individual with their disease, assessing the presence of problematic symptoms. It can also be used in those situations where other self-report measures, such as the HB or PT, cannot be used (e.g., in the presence of stomas). Furthermore, our evaluation in a clinical sample suggested greater accuracy of the MIBDI in re ecting disease activity over time than the HB or PT. at is, many of the patients who were categorized as inactive based on the HB or PT were classi ed as active based on the MIBDI, and had clear chart evidence of disease are occurring in the previous 6 months, including initiation of new medication. is nding highlights a disadvantage of the current indexes in use, such as the HB, PT, CDAI, or IBDQ, that the inactive disease recently achieved through prednisone or other treatment is not able to be differentiated from longstanding ' true ' remission, even though the experience of these two scenarios may be quite di erent for the patient.
ere was striking stability of IBD symptomatology across time. Given that these data are drawn from a population-based cohort, it provides some indication of the experiences of IBD ' in the community ' in the context of usual care. With at least half of those with IBD experiencing symptoms occasionally to daily in a 6-month time frame, it raises the question of whether treatment may be suboptimal or whether many accept some level of symptoms as part of their disease experience. is aspect of symptom tolerance vs. suboptimal therapy warrants further exploration. Ultimately, of course, an index cannot be determined to be " valid " in an absolute sense. Rather it can be determined to have utility for particular circumstances (36) . In conducting longitudinal research in patients with IBD, researchers need to choose the disease measures based on what is critical for the research. Consideration of endoscopic in ammation and healing as an important therapeutic target has only recently emerged as a potentially important goal (38) . If this is the goal in a longitudinal study, then endoscopy or imaging should be incorporated. In many longitudinal studies, however, repeated imaging or biopsies may be too expensive and intrusive. If symptom status and related disease interference are key outcomes in a study, then patient-report measures of disease activity can be quite appropriate and have strong advantages.
e MIBDI has the further advantage that it encompasses a 6-month period, which may be highly relevant in many longitudinal studies. A potential limitation of the MIBDI is the lack of detail about speci c symptoms. In our study, we also asked about common IBD-related symptoms and severity over the same time frame, which could be used as an adjunct measure when that type of detail is needed. Another limitation is the potential for a recency e ect biasing the MIBDI 6-month report.
at is, recent disease activity could in uence recall and characterization of disease in the previous 6 months and that will need to be addressed empirically in subsequent work with the measure.
In conclusion, there is no one absolute way to capture disease activity. The best measure for a particular situation may depend on the research or clinical goals. The MIBDI meets the following goals that are previously identified in the literature for an ideal disease activity measurement tool: (a) it has well-understood operating characteristics and a dynamic range to accurately reflect gradations of illness and (b) it is reproducible, valid and responsive (39) . The advantages of the MIBDI described in this study are its brevity, 6-month time frame, focus on the person ' s experience of the frequency of significant symptoms, and the strong agreement with widely used disease activity measures and proxy markers of disease. The MIBDI had high levels of sensitivity across a 2-year time period, indicating that the MIBDI relates consistently to the existing measures of disease activity. There was some indication that the MIBDI could potentially be used for those whose stoma, short bowel syndrome, or intestinal stricture may preclude the use of symptom-based activity indexes such as the CDAI, HB, and PT. Finally, our assessment of the MIBDI in a clinical sample strengthens the evidence for the MIBDI as a versatile measure of disease activity.
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